12 Month Price Forecast For MDXG
Distance to MDXG Price Forecasts
MDXG Price Momentum
๐ค Considering MiMedx (MDXG)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 15, 2025 5:56 PM UTC
MDXG Analyst Ratings & Price Targets
Based on our analysis of 6 Wall Street analysts, MDXG has a bullish consensus with a median price target of $13.00 (ranging from $12.00 to $16.00). Currently trading at $8.40, the median forecast implies a 54.8% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Chase Knickerbocker at Craig-Hallum, suggesting a 42.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MDXG Analyst Consensus
MDXG Price Target Range
Latest MDXG Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MDXG.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Aug 1, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $11.00 |
Aug 1, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $12.00 |
Jul 2, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Initiates | $11.00 |
May 1, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $11.00 |
Mar 7, 2024 | Lake Street | Brooks O'Neil | Buy | Initiates | $12.00 |
Mar 1, 2024 | Mizuho | Anthony Petrone | Buy | Maintains | $14.00 |
Oct 31, 2023 | Mizuho | Anthony Petrone | Buy | Maintains | $12.00 |
Oct 27, 2023 | Craig-Hallum | Chase Knickerbocker | Buy | Initiates | $12.00 |
Aug 2, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $11.00 |
Aug 2, 2023 | Mizuho | Anthony Petrone | Buy | Maintains | $12.00 |
Jun 21, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $8.00 |
May 3, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $9.50 |
Mar 2, 2023 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $8.00 |
Oct 13, 2022 | Mizuho | Anthony Petrone | Buy | Initiates | $7.00 |
Sep 7, 2022 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $8.00 |
Sep 14, 2021 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Maintains | $8.50 |
Jul 26, 2021 | Northland Capital Markets | Outperform | Initiates | $0.00 | |
Mar 19, 2021 | HC Wainwright & Co. | Buy | Initiates | $0.00 | |
Feb 26, 2018 | Lake Street | Hold | Downgrade | $0.00 | |
Feb 20, 2018 | Needham | Hold | Downgrade | $0.00 |
Stocks Similar to MiMedx Group, Inc.
The following stocks are similar to MiMedx based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
MiMedx Group, Inc. (MDXG) Financial Data
MiMedx Group, Inc. has a market capitalization of $1.23B with a P/E ratio of 14.7x. The company generates $342.80M in trailing twelve-month revenue with a 25.8% profit margin.
Revenue growth is +2.9% quarter-over-quarter, while maintaining an operating margin of +13.6% and return on equity of +62.5%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

MiMedx Group, Inc. (MDXG) Company Overview
About MiMedx Group, Inc.
Develops and distributes placental tissue allografts.
The company processes human placental tissues using its proprietary PURION process, creating allografts that retain biological properties. It generates revenue by selling products like EpiFix and AmnioFix through a direct sales force, independent agents, and distributors, primarily in the U.S.
Founded in 2006 and headquartered in Marietta, Georgia, MiMedx offers products targeting wound care, burns, and surgical recovery, addressing critical healthcare needs.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
895
CEO
Mr. Joseph H. Capper
Country
United States
IPO Year
2008
Website
www.mimedx.comMiMedx Group, Inc. (MDXG) Latest News & Analysis
MiMedx (MDXG) is highlighted as a potential choice for short-term investors, having passed a trading strategy screen for fundamentally sound stocks.
MiMedx's recent performance and solid fundamentals suggest potential for short-term gains, making it an attractive option for traders seeking quick profits.
MiMedx (MDXG) is identified as a strong candidate for investors, having passed the "Recent Price Strength" screening, indicating potential for continued upward momentum.
MiMedx (MDXG) shows strong recent performance, indicating momentum and potential for continued growth, attracting investors seeking upward-trending stocks.
Analysts' price targets for MiMedx (MDXG) suggest a 37.1% upside, supported by strong agreement in raised earnings estimates among analysts.
Analysts' price targets suggesting a 37.1% upside, along with raised earnings estimates, signal potential growth for MiMedx (MDXG), attracting investor interest.
MiMedx Group, Inc. announced that over 200 unproven skin substitutes will no longer be covered under revised Local Coverage Determinations, favoring clinically effective products.
The exclusion of unproven skin substitutes from coverage may boost MiMedx's sales of clinically effective products, potentially enhancing revenue and stock performance.
MiMedx (MDXG) is identified as a potential option for short-term investors, having passed a trading strategy screen focused on fundamentally sound stocks.
MiMedx's recent price trend and strong fundamentals signal potential short-term gains, attracting traders seeking quick investment opportunities.
MiMedx (MDXG) has a consensus price target suggesting a 77.9% upside. Recent upward revisions in earnings estimates may indicate potential near-term growth.
A 77.9% upside target and positive earnings estimate revisions suggest MiMedx (MDXG) may experience significant short-term price appreciation, attracting investor interest.
Frequently Asked Questions About MDXG Stock
What is MiMedx Group, Inc.'s (MDXG) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, MiMedx Group, Inc. (MDXG) has a median price target of $13.00. The highest price target is $16.00 and the lowest is $12.00.
Is MDXG stock a good investment in 2025?
According to current analyst ratings, MDXG has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.40. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for MDXG stock?
Wall Street analysts predict MDXG stock could reach $13.00 in the next 12 months. This represents a 54.8% increase from the current price of $8.40. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is MiMedx Group, Inc.'s business model?
The company processes human placental tissues using its proprietary PURION process, creating allografts that retain biological properties. It generates revenue by selling products like EpiFix and AmnioFix through a direct sales force, independent agents, and distributors, primarily in the U.S.
What is the highest forecasted price for MDXG MiMedx Group, Inc.?
The highest price target for MDXG is $16.00 from at , which represents a 90.5% increase from the current price of $8.40.
What is the lowest forecasted price for MDXG MiMedx Group, Inc.?
The lowest price target for MDXG is $12.00 from Chase Knickerbocker at Craig-Hallum, which represents a 42.9% increase from the current price of $8.40.
What is the overall MDXG consensus from analysts for MiMedx Group, Inc.?
The overall analyst consensus for MDXG is bullish. Out of 6 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are MDXG stock price projections?
Stock price projections, including those for MiMedx Group, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.